# Outsee

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/outsee

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.outsee.co.uk
- Total disclosed funding: $6.1M
- Latest round: Seed (Jan 12, 2026)
- Investors on record: 4

## About

Based in the UK, Outsee Limited operates as a provider of advanced genomic analysis solutions, utilizing predictive AI technology to enhance patient diagnosis and stratification. Founded in 2023, Outsee Limited is headquartered in Cambridge, UK. The company specializes in predictive genomic analysis, leveraging its innovative platform for enhanced healthcare solutions. In January 2026, Outsee Limited raised GBP 2.5 million in seed funding led by Ahren Innovation Capital, with participation from Kadmos Capital, Panacea Venture, and Empirical Ventures. Outsee's primary product offering is Nomaly, a predictive AI engine designed for genomic analysis. Unlike traditional methods that rely on known genetic associations, Nomaly predicts disease and phenotype directly from a single genome, leveraging fundamental principles of molecular and cell biology. By uncovering the biological mechanisms that drive and modulate disease, Nomaly enables healthcare providers to more accurately identify and categorize patients, particularly in complex genetic scenarios involving multi-variant effects and mechanistically cooperative interactions. This technology addresses significant challenges in genomic analysis by providing insights that conventional association-based methods struggle to deliver, especially in diverse patient populations. OutSee's solutions cater to a range of clients, including healthcare institutions and research organizations in North America, Europe, and Asia, enhancing their capabilities in precision medicine and patient stratification. OutSee's revenue model is centered around B2B transactions, primarily involving partnerships with healthcare providers, research institutions, and biotechnology firms. The company engages clients through subscription-based access to its Nomaly platform, allowing users to integrate the predictive capabilities into their genomic research and clinical workflows. These partnerships facilitate a steady stream of revenue as clients utilize Nomaly's technology to enhance their genomic analyses and patient care strategies. Specific pricing plans for Nomaly's offerings are structured to accommodate the varying needs of clients, ensuring scalability and accessibility for both large healthcare systems and smaller research entities. The company will use the funding from January 2026 to advance its data-backed therapeutic targets through experimental validation, build a pipeline of drug candidates, and continue R&D to improve its Nomaly platform.

## Funding rounds

- Seed, Jan 12, 2026, $3.4M — Panacea Venture, Ahren Innovation Capital, Kadmos Capital, Empirical Ventures
- Seed, Dec 13, 2024, $2.7M — Panacea Venture, Ahren Innovation Capital, Kadmos Capital, Empirical Ventures

## Investors

- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Seed
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Seed
- Kadmos Capital (https://capitalatlas.ai/funds/kadmos-capital) — Seed
- Empirical Ventures (https://capitalatlas.ai/funds/empirical-ventures) — Seed